Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

14.55USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$14.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,638
52-wk High
$30.35
52-wk Low
$13.20

Latest Key Developments (Source: Significant Developments)

Lannett Acquires Portfolio Of Generic Products From Endo International
Monday, 7 May 2018 

May 7 (Reuters) - Lannett Company Inc ::LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL.LANNETT COMPANY INC - TRANSACTION INCLUDES 23 APPROVED AND 1 PENDING DRUG PRODUCT APPLICATIONS, PRIMARILY ORAL SOLUTIONS.LANNETT - ACQUIRED 23 APPROVED AND ONE PENDING DRUG PRODUCT APPLICATIONS FROM UNIT OF ENDO FOR UPFRONT PAYMENT PLUS FUTURE MILESTONE PAYMENTS.LANNETT - EXPECT TO BEGIN LAUNCHING PRODUCTS, AFTER TRANSFER ACTIVITIES ARE COMPLETED, REGULATORY FILINGS MADE, ESTIMATED TO BE IN H2 2019.  Full Article

Lannett Appoints Patrick Lepore Chairman Of Board
Monday, 30 Apr 2018 

April 30 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES CHANGES TO BOARD OF DIRECTORS.SAYS JOHN C. CHAPMAN APPOINTED TO THE BOARD.SAYS PATRICK LEPORE APPOINTED CHAIRMAN OF THE BOARD.LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD.  Full Article

Lannett Appoints Timothy Crew As CEO
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Lannett Company Inc ::LANNETT APPOINTS TIMOTHY C. CREW AS CEO.LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY.LANNETT COMPANY INC - BOARD NAMED TIMOTHY C. CREW AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 2, 2018.  Full Article

Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT.LANNETT COMPANY - ‍FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JULY 21, 2018, TEN MONTHS FROM OFFICIAL NDA SUBMISSION DATE​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Lannett Company Inc :Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance.Q1 adjusted earnings per share $0.60.Q1 earnings per share $0.35.Q1 earnings per share view $0.52 -- Thomson Reuters I/B/E/S.Q1 sales $155 million versus I/B/E/S view $153.6 million.Lannett Company Inc sees fiscal 2018 ‍net sales of $710 million to $720 million, up from $655 million to $665 million​.Lannett Company Inc sees fiscal 2018 ‍capital expenditures of $65 million to $75 million.Q1 revenue view $153.6 million -- Thomson Reuters I/B/E/S.FY2018 revenue view $658.6 million -- Thomson Reuters I/B/E/S.  Full Article

Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Deerfield Management L.P: :Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​.  Full Article

Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​.Lannett - believe price-fixing allegations about a single product named in complaint that co sells are "meritless​".  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Lannett Q4 adjusted earnings per share $0.73
Tuesday, 23 Aug 2016 

Lannett Company Inc : Lannett announces record net sales for fiscal 2016 fourth-quarter and full-year . Q4 adjusted earnings per share $0.73 . Q4 earnings per share $0.10 . Q4 sales $168.9 million versus i/b/e/s view $161.6 million . Q4 earnings per share view $0.59 -- Thomson Reuters I/B/E/S . Lannett Company Inc Sees fiscal 2017 capital expenditures $55 million to $65 million . Lannett Company Inc sees FY 2017 net sales to be between $690 million and $700 million . Lannett company inc sees fiscal 2017 gaap gross margin percentage 50% to 51% .Lannett Company Inc sees fiscal 2017 adjusted gross margin percentage 55% to 56%.  Full Article

BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules

* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG